JP7545955B2 - インフルエンザｈａスプリットワクチンの製造方法 - Google Patents
インフルエンザｈａスプリットワクチンの製造方法 Download PDFInfo
- Publication number
- JP7545955B2 JP7545955B2 JP2021504119A JP2021504119A JP7545955B2 JP 7545955 B2 JP7545955 B2 JP 7545955B2 JP 2021504119 A JP2021504119 A JP 2021504119A JP 2021504119 A JP2021504119 A JP 2021504119A JP 7545955 B2 JP7545955 B2 JP 7545955B2
- Authority
- JP
- Japan
- Prior art keywords
- influenza
- split vaccine
- split
- vaccine
- producing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960005486 vaccine Drugs 0.000 title claims description 265
- 206010022000 influenza Diseases 0.000 title claims description 149
- 238000004519 manufacturing process Methods 0.000 title claims description 81
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 100
- 238000010306 acid treatment Methods 0.000 claims description 53
- 230000034217 membrane fusion Effects 0.000 claims description 36
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 35
- 239000002953 phosphate buffered saline Substances 0.000 claims description 35
- 241000712461 unidentified influenza virus Species 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 25
- 239000007979 citrate buffer Substances 0.000 claims description 16
- 239000007983 Tris buffer Substances 0.000 claims description 11
- 239000012528 membrane Substances 0.000 claims description 11
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 10
- 201000010740 swine influenza Diseases 0.000 claims description 10
- 206010069767 H1N1 influenza Diseases 0.000 claims description 9
- 230000000799 fusogenic effect Effects 0.000 claims description 8
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 101710154606 Hemagglutinin Proteins 0.000 claims description 3
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 3
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 3
- 101710176177 Protein A56 Proteins 0.000 claims description 3
- 239000000185 hemagglutinin Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 58
- 241000699670 Mus sp. Species 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 18
- 239000002245 particle Substances 0.000 description 17
- 238000002255 vaccination Methods 0.000 description 15
- 241000700605 Viruses Species 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 12
- 230000000890 antigenic effect Effects 0.000 description 11
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 238000011725 BALB/c mouse Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 229920001213 Polysorbate 20 Polymers 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 8
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 238000011740 C57BL/6 mouse Methods 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 6
- 229920000053 polysorbate 80 Polymers 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 238000013019 agitation Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000712431 Influenza A virus Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 101710198474 Spike protein Proteins 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000007793 ph indicator Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- YYGNTYWPHWGJRM-AAJYLUCBSA-N squalene Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C=C(/C)CC\C=C(/C)CCC=C(C)C YYGNTYWPHWGJRM-AAJYLUCBSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 1
- YCAGGFXSFQFVQL-UHFFFAOYSA-N Endothion Chemical compound COC1=COC(CSP(=O)(OC)OC)=CC1=O YCAGGFXSFQFVQL-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 241000845082 Panama Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940033324 influenza A vaccine Drugs 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- CEQFOVLGLXCDCX-WUKNDPDISA-N methyl red Chemical compound C1=CC(N(C)C)=CC=C1\N=N\C1=CC=CC=C1C(O)=O CEQFOVLGLXCDCX-WUKNDPDISA-N 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019038662 | 2019-03-04 | ||
| JP2019038662 | 2019-03-04 | ||
| PCT/JP2020/008974 WO2020179797A1 (ja) | 2019-03-04 | 2020-03-03 | インフルエンザｈａスプリットワクチンの製造方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020179797A1 JPWO2020179797A1 (en]) | 2020-09-10 |
| JPWO2020179797A5 JPWO2020179797A5 (en]) | 2023-08-03 |
| JP7545955B2 true JP7545955B2 (ja) | 2024-09-05 |
Family
ID=72337458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021504119A Active JP7545955B2 (ja) | 2019-03-04 | 2020-03-03 | インフルエンザｈａスプリットワクチンの製造方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220152191A1 (en]) |
| EP (1) | EP3936147A4 (en]) |
| JP (1) | JP7545955B2 (en]) |
| KR (1) | KR20210135261A (en]) |
| CN (1) | CN114096273A (en]) |
| AU (1) | AU2020233456A1 (en]) |
| BR (1) | BR112021017310A8 (en]) |
| CA (1) | CA3132578A1 (en]) |
| EA (1) | EA202192398A1 (en]) |
| IL (1) | IL285984A (en]) |
| MX (1) | MX2021010685A (en]) |
| PH (1) | PH12021552094A1 (en]) |
| SG (1) | SG11202109566XA (en]) |
| WO (1) | WO2020179797A1 (en]) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019311965A1 (en) | 2018-07-23 | 2021-02-25 | Japan As Represented By Director General Of National Institute Of Infectious Diseases | Composition containing influenza vaccine |
| KR20220098370A (ko) * | 2019-11-07 | 2022-07-12 | 세퀴러스 유케이 리미티드 | 감소된 입자 크기를 가지는 바이러스 백신을 제조하기 위한 조성물 및 방법 |
| TW202506714A (zh) * | 2023-04-26 | 2025-02-16 | 國立感染症研究所長代表之日本國 | 抗流感抗體 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2374894B1 (en) * | 1993-09-13 | 2014-09-17 | Protein Sciences Corporation | A method for producing influenza hemagglutinin multivalent vaccines |
| US20230201329A1 (en) * | 2006-07-17 | 2023-06-29 | Glaxosmithkline Biologicals Sa | Influenza vaccine |
| US20090181078A1 (en) * | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| US9452209B2 (en) * | 2007-04-20 | 2016-09-27 | Glaxosmithkline Biologicals Sa | Influenza vaccine |
| CN102223895B (zh) * | 2008-11-25 | 2014-11-05 | 巴克斯特保健股份有限公司 | 生产pH稳定的包膜病毒的方法 |
| CN102406931B (zh) * | 2011-11-25 | 2014-02-05 | 成都康华生物制品有限公司 | 大流行流感病毒裂解疫苗 |
| CN104302317B (zh) * | 2012-05-16 | 2016-07-06 | Kj生物科学有限公司 | 新型和改进的流感疫苗 |
| KR20140118682A (ko) | 2013-03-29 | 2014-10-08 | (주)셀트리온 | 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물 |
| JP2018517405A (ja) * | 2015-05-04 | 2018-07-05 | エピバックス インコーポレーテッド | インフルエンザａ／上海／２／２０１３ ｈ７配列の改変ｈ７赤血球凝集素糖タンパク質 |
| WO2017056494A1 (en) * | 2015-09-29 | 2017-04-06 | Sumitomo Dainippon Pharma Co., Ltd. | Adenine conjugate compounds and their use as vaccine adjuvants |
| EP3603619B1 (en) * | 2017-03-29 | 2025-08-13 | Sumitomo Pharma Co., Ltd. | Vaccine adjuvant formulation |
| JP7403733B2 (ja) * | 2017-09-04 | 2023-12-25 | 国立感染症研究所長 | インフルエンザｈａスプリットワクチンの製造方法 |
| AU2019311965A1 (en) * | 2018-07-23 | 2021-02-25 | Japan As Represented By Director General Of National Institute Of Infectious Diseases | Composition containing influenza vaccine |
| CN113194986A (zh) * | 2018-12-26 | 2021-07-30 | 大日本住友制药株式会社 | 包括疫苗佐剂的制剂 |
| CA3131551A1 (en) * | 2019-02-28 | 2020-09-03 | Novavax, Inc. | Methods for preventing disease or disorder caused by rsv infection |
-
2020
- 2020-03-03 EP EP20766488.9A patent/EP3936147A4/en active Pending
- 2020-03-03 BR BR112021017310A patent/BR112021017310A8/pt unknown
- 2020-03-03 PH PH1/2021/552094A patent/PH12021552094A1/en unknown
- 2020-03-03 WO PCT/JP2020/008974 patent/WO2020179797A1/ja active Application Filing
- 2020-03-03 KR KR1020217030986A patent/KR20210135261A/ko active Pending
- 2020-03-03 CN CN202080033434.5A patent/CN114096273A/zh active Pending
- 2020-03-03 JP JP2021504119A patent/JP7545955B2/ja active Active
- 2020-03-03 AU AU2020233456A patent/AU2020233456A1/en active Pending
- 2020-03-03 SG SG11202109566X patent/SG11202109566XA/en unknown
- 2020-03-03 MX MX2021010685A patent/MX2021010685A/es unknown
- 2020-03-03 EA EA202192398A patent/EA202192398A1/ru unknown
- 2020-03-03 CA CA3132578A patent/CA3132578A1/en active Pending
- 2020-03-03 US US17/435,590 patent/US20220152191A1/en active Pending
-
2021
- 2021-08-31 IL IL285984A patent/IL285984A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021017310A2 (en]) | 2021-11-16 |
| KR20210135261A (ko) | 2021-11-12 |
| BR112021017310A8 (pt) | 2022-12-06 |
| SG11202109566XA (en) | 2021-10-28 |
| WO2020179797A1 (ja) | 2020-09-10 |
| MX2021010685A (es) | 2021-12-10 |
| EP3936147A1 (en) | 2022-01-12 |
| AU2020233456A1 (en) | 2021-10-07 |
| EA202192398A1 (ru) | 2021-11-23 |
| IL285984A (en) | 2021-10-31 |
| PH12021552094A1 (en) | 2022-05-30 |
| JPWO2020179797A1 (en]) | 2020-09-10 |
| US20220152191A1 (en) | 2022-05-19 |
| CA3132578A1 (en) | 2020-09-10 |
| EP3936147A4 (en) | 2022-09-28 |
| CN114096273A (zh) | 2022-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11793871B2 (en) | Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof | |
| JP7545955B2 (ja) | インフルエンザｈａスプリットワクチンの製造方法 | |
| JP7403733B2 (ja) | インフルエンザｈａスプリットワクチンの製造方法 | |
| CN112043825A (zh) | 一种基于新型冠状病毒突刺蛋白s1区域预防新型冠状病毒感染的亚单位疫苗 | |
| JP7382634B2 (ja) | 交差免疫抗原ワクチン及びその調製方法 | |
| US20230406910A1 (en) | Method for producing influenza ha split vaccine | |
| TWI857017B (zh) | 流感ha裂解疫苗之製造方法 | |
| CN115850395A (zh) | 一种流感病毒通用型纳米颗粒疫苗及其制备方法 | |
| EA045912B1 (ru) | Способ приготовления сплит-вакцины на основе гемагглютинина гриппа | |
| HK40068192A (en) | Method for preparing influenza ha split vaccine | |
| HK40032891A (en) | Method for producing influenza ha split vaccine | |
| EA045852B1 (ru) | Способ получения сплит-вакцины с ha гриппа | |
| WO2025092866A1 (zh) | 一种多价流感mRNA疫苗 | |
| JP2023515829A (ja) | 小児対象のための高用量インフルエンザワクチン | |
| RU2451027C2 (ru) | Рекомбинантная вакцина против вируса "свиного" гриппа h1n1 и спсоб ее получения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230302 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230725 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240227 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240426 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240730 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240826 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7545955 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |